ebselen has been researched along with Inflammation in 28 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compared the influence of a dietary surplus of Se and pretreatment with ebselen, a mimic of the selenoenzyme glutathione peroxidase, on IRI-induced tissue damage and inflammation." | 7.83 | Selenium Pretreatment for Mitigation of Ischemia/Reperfusion Injury in Cardiovascular Surgery: Influence on Acute Organ Damage and Inflammatory Response. ( Akhyari, P; Bilgic, E; Boeken, U; Döhrn, L; Engels, M; Kellermann, K; Lichtenberg, A; Pinto, A; Steinbrenner, H; Wollschläger, L, 2016) |
| "The aim of this study was to evaluate the effects of diphenyl diselenide (PhSe)2 and ebselen (EB) in ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in rats." | 7.83 | Diphenyl diselenide attenuates oxidative stress and inflammatory parameters in ulcerative colitis: A comparison with ebselen. ( Danielski, LG; Florentino, D; Giustina, AD; Goldim, MP; Leffa, DD; Mendonça, MG; Michels, M; Pereira, GW; Pereira, VD; Petronilho, F; Piacentini, B; Rocha, JB; Tournier, M; Vieira, A, 2016) |
| "We investigated the pro-inflammatory response mediated by TNFalpha in glioblastoma and whether treatment with organoselenium Ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]one) can affect TNFalpha induced inflammatory response." | 7.75 | Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma. ( Ghosh, A; Hossain Sk, U; Joseph, C; Koul, N; Sen, E; Sharma, V; Tewari, R, 2009) |
| " In vivo, ebselen is a weak oral inhibitor of carrageenan paw oedema and adjuvant arthritis in the rat, differentiating it from classical NSAIDs such as indomethacin and diclofenac." | 7.67 | Ebselen: a new approach to the inhibition of peroxide-dependent inflammation. ( Kuhl, P; Leyck, S; Parnham, MJ; Schalkwijk, J; van den Berg, WB, 1987) |
| "Ebselen is a seleno-organic compound that has been demonstrated to have antioxidant and anti-inflammatory properties." | 5.48 | Ebselen suppresses inflammation induced by Helicobacter pylori lipopolysaccharide via the p38 mitogen-activated protein kinase signaling pathway. ( Gong, C; Li, G; Meng, W; Shi, M; Wang, T; Wang, Y; Wei, J; Xu, L, 2018) |
| "Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties that is currently being examined in clinical trials to prevent and treat various diseases, including atherosclerosis, stroke, and cancer." | 5.43 | Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo. ( Baek, JM; Kim, JY; Lee, MS; Oh, J; Yoon, KH, 2016) |
| "Ebselen pretreatment inhibited neutrophil influx and activation as assessed by BAL fluid cellularity and myeloperoxidase activity in cell-free BAL and BAL cell homogenates." | 5.31 | Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. ( Belvisi, MG; Birrell, MA; Chen, B; Dabrowski, D; De Sanctis, GT; Foster, ML; Haddad, el-B; McCluskie, K; Pecoraro, M; Underwood, S; Webber, SE, 2002) |
| " We compared the influence of a dietary surplus of Se and pretreatment with ebselen, a mimic of the selenoenzyme glutathione peroxidase, on IRI-induced tissue damage and inflammation." | 3.83 | Selenium Pretreatment for Mitigation of Ischemia/Reperfusion Injury in Cardiovascular Surgery: Influence on Acute Organ Damage and Inflammatory Response. ( Akhyari, P; Bilgic, E; Boeken, U; Döhrn, L; Engels, M; Kellermann, K; Lichtenberg, A; Pinto, A; Steinbrenner, H; Wollschläger, L, 2016) |
| "The aim of this study was to evaluate the effects of diphenyl diselenide (PhSe)2 and ebselen (EB) in ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) in rats." | 3.83 | Diphenyl diselenide attenuates oxidative stress and inflammatory parameters in ulcerative colitis: A comparison with ebselen. ( Danielski, LG; Florentino, D; Giustina, AD; Goldim, MP; Leffa, DD; Mendonça, MG; Michels, M; Pereira, GW; Pereira, VD; Petronilho, F; Piacentini, B; Rocha, JB; Tournier, M; Vieira, A, 2016) |
| "We investigated the pro-inflammatory response mediated by TNFalpha in glioblastoma and whether treatment with organoselenium Ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]one) can affect TNFalpha induced inflammatory response." | 3.75 | Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma. ( Ghosh, A; Hossain Sk, U; Joseph, C; Koul, N; Sen, E; Sharma, V; Tewari, R, 2009) |
| " In vivo, ebselen is a weak oral inhibitor of carrageenan paw oedema and adjuvant arthritis in the rat, differentiating it from classical NSAIDs such as indomethacin and diclofenac." | 3.67 | Ebselen: a new approach to the inhibition of peroxide-dependent inflammation. ( Kuhl, P; Leyck, S; Parnham, MJ; Schalkwijk, J; van den Berg, WB, 1987) |
| "Treatment with ebselen and silver ion significantly reduced bacterial loads, down-regulated the expression levels of tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) on-site and decreased white/red blood cell counts in mild cystitis model mice, which demonstrated the anti-inflammatory property of these agents." | 1.56 | Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion. ( Dong, C; Lu, Q; Wang, J; Wang, P; Xie, Z; Zhao, Y; Zhou, J; Zou, L, 2020) |
| "Ebselen is a seleno-organic compound that has been demonstrated to have antioxidant and anti-inflammatory properties." | 1.48 | Ebselen suppresses inflammation induced by Helicobacter pylori lipopolysaccharide via the p38 mitogen-activated protein kinase signaling pathway. ( Gong, C; Li, G; Meng, W; Shi, M; Wang, T; Wang, Y; Wei, J; Xu, L, 2018) |
| "Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties that is currently being examined in clinical trials to prevent and treat various diseases, including atherosclerosis, stroke, and cancer." | 1.43 | Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo. ( Baek, JM; Kim, JY; Lee, MS; Oh, J; Yoon, KH, 2016) |
| "Ebselen pretreatment inhibited neutrophil influx and activation as assessed by BAL fluid cellularity and myeloperoxidase activity in cell-free BAL and BAL cell homogenates." | 1.31 | Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation. ( Belvisi, MG; Birrell, MA; Chen, B; Dabrowski, D; De Sanctis, GT; Foster, ML; Haddad, el-B; McCluskie, K; Pecoraro, M; Underwood, S; Webber, SE, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 6 (21.43) | 18.2507 |
| 2000's | 4 (14.29) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 5 (17.86) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Trivedi-Parmar, V | 1 |
| Jorgensen, WL | 1 |
| Polianskyte-Prause, Z | 1 |
| Tolvanen, TA | 1 |
| Lindfors, S | 1 |
| Kon, K | 1 |
| Hautala, LC | 1 |
| Wang, H | 1 |
| Wada, T | 1 |
| Tsuneki, H | 1 |
| Sasaoka, T | 1 |
| Lehtonen, S | 1 |
| Garland, M | 1 |
| Hryckowian, AJ | 1 |
| Tholen, M | 1 |
| Bender, KO | 1 |
| Van Treuren, WW | 1 |
| Loscher, S | 1 |
| Sonnenburg, JL | 1 |
| Bogyo, M | 1 |
| Wang, P | 1 |
| Wang, J | 1 |
| Xie, Z | 1 |
| Zhou, J | 2 |
| Lu, Q | 1 |
| Zhao, Y | 1 |
| Dong, C | 1 |
| Zou, L | 1 |
| Zhang, J | 1 |
| Saad, R | 1 |
| Taylor, EW | 1 |
| Rayman, MP | 1 |
| Mao, H | 1 |
| Chen, Y | 1 |
| Xu, L | 1 |
| Gong, C | 1 |
| Li, G | 1 |
| Wei, J | 1 |
| Wang, T | 1 |
| Meng, W | 1 |
| Shi, M | 1 |
| Wang, Y | 1 |
| Vlahos, R | 1 |
| Bozinovski, S | 1 |
| Xu, H | 1 |
| Huang, K | 1 |
| Baek, JM | 1 |
| Kim, JY | 1 |
| Yoon, KH | 1 |
| Oh, J | 1 |
| Lee, MS | 1 |
| Steinbrenner, H | 1 |
| Bilgic, E | 1 |
| Pinto, A | 1 |
| Engels, M | 1 |
| Wollschläger, L | 1 |
| Döhrn, L | 1 |
| Kellermann, K | 1 |
| Boeken, U | 1 |
| Akhyari, P | 1 |
| Lichtenberg, A | 1 |
| Petronilho, F | 1 |
| Michels, M | 1 |
| Danielski, LG | 1 |
| Goldim, MP | 1 |
| Florentino, D | 1 |
| Vieira, A | 1 |
| Mendonça, MG | 1 |
| Tournier, M | 1 |
| Piacentini, B | 1 |
| Giustina, AD | 1 |
| Leffa, DD | 1 |
| Pereira, GW | 1 |
| Pereira, VD | 1 |
| Rocha, JB | 1 |
| Parnham, MJ | 4 |
| Tewari, R | 1 |
| Sharma, V | 1 |
| Koul, N | 1 |
| Ghosh, A | 1 |
| Joseph, C | 1 |
| Hossain Sk, U | 1 |
| Sen, E | 1 |
| Gierer, P | 1 |
| Röther, J | 1 |
| Mittlmeier, T | 1 |
| Gradl, G | 1 |
| Vollmar, B | 1 |
| Santos, AP | 1 |
| Lucas, RL | 1 |
| Andrade, V | 1 |
| Mateus, ML | 1 |
| Milatovic, D | 1 |
| Aschner, M | 1 |
| Batoreu, MC | 1 |
| Schewe, T | 1 |
| Gao, JX | 1 |
| Issekutz, AC | 1 |
| Pratta, MA | 1 |
| Ackerman, NR | 1 |
| Arner, EC | 1 |
| Moutet, M | 1 |
| d'Alessio, P | 1 |
| Malette, P | 1 |
| Devaux, V | 1 |
| Chaudière, J | 1 |
| Kono, H | 1 |
| Arteel, GE | 1 |
| Rusyn, I | 1 |
| Sies, H | 1 |
| Thurman, RG | 1 |
| Nakamura, Y | 1 |
| Feng, Q | 1 |
| Kumagai, T | 1 |
| Torikai, K | 1 |
| Ohigashi, H | 1 |
| Osawa, T | 1 |
| Noguchi, N | 1 |
| Niki, E | 1 |
| Uchida, K | 1 |
| Haddad, el-B | 1 |
| McCluskie, K | 1 |
| Birrell, MA | 1 |
| Dabrowski, D | 1 |
| Pecoraro, M | 1 |
| Underwood, S | 1 |
| Chen, B | 1 |
| De Sanctis, GT | 1 |
| Webber, SE | 1 |
| Foster, ML | 1 |
| Belvisi, MG | 1 |
| Griffiths, HR | 1 |
| Dowling, EJ | 2 |
| Sahinoglu, T | 1 |
| Blake, DR | 2 |
| Parnham, M | 1 |
| Lunec, J | 1 |
| Leyck, S | 2 |
| Graf, E | 2 |
| Kuhl, P | 1 |
| Schalkwijk, J | 1 |
| van den Berg, WB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease[NCT02603081] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus[NCT00762671] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects[NCT01452607] | Phase 1 | 32 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for ebselen and Inflammation
| Article | Year |
|---|---|
Selenium and selenoproteins in viral infection with potential relevance to COVID-19.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Coronavirus 3C Proteases; COVID-19; COVID- | 2020 |
Noise-Induced Hearing Loss: Updates on Molecular Targets and Potential Interventions.
Topics: Animals; Autophagy; Calcium; Clinical Trials, Phase II as Topic; DNA Repair; Drugs, Investigational; | 2021 |
Glutathione peroxidase-1 as a novel therapeutic target for COPD.
Topics: Animals; Antioxidants; Azoles; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; Inflamma | 2013 |
Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azoles; Chromium Compounds; Cysteine; Diabetes Mellitus, Ty | 2016 |
Molecular actions of ebselen--an antiinflammatory antioxidant.
Topics: Animals; Antioxidants; Azoles; Enzyme Inhibitors; Inflammation; Isoindoles; Lipid Peroxidation; Mole | 1995 |
The pharmacology of ebselen.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Glutathione Peroxidase; Inflammation; Isoi | 1991 |
Seleno-organic compounds and the therapy of hydroperoxide-linked pathological conditions.
Topics: Animals; Azoles; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Inflammation; Isoindoles; Organo | 1987 |
21 other studies available for ebselen and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.
Topics: Drug Discovery; Enzyme Inhibitors; Humans; Inflammation; Intramolecular Oxidoreductases; Macrophage | 2018 |
Ebselen enhances insulin sensitivity and decreases oxidative stress by inhibiting SHIP2 and protects from inflammation in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Inflammation; Insulin; Insulin Resistance; Isoindoles; Mic | 2022 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
Depletion of multidrug-resistant uropathogenic Escherichia coli BC1 by ebselen and silver ion.
Topics: Animals; Anti-Bacterial Agents; Azoles; Cystitis; Disease Models, Animal; Drug Resistance, Multiple, | 2020 |
Ebselen suppresses inflammation induced by Helicobacter pylori lipopolysaccharide via the p38 mitogen-activated protein kinase signaling pathway.
Topics: Azoles; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Helicobacter pylori; Humans; Infla | 2018 |
Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Topics: Animals; Azoles; Bone Resorption; Cell Differentiation; Inflammation; Isoindoles; Lipopolysaccharide | 2016 |
Selenium Pretreatment for Mitigation of Ischemia/Reperfusion Injury in Cardiovascular Surgery: Influence on Acute Organ Damage and Inflammatory Response.
Topics: Animals; Azoles; Cardiopulmonary Bypass; Dietary Supplements; Hypothermia, Induced; Inflammation; Is | 2016 |
Diphenyl diselenide attenuates oxidative stress and inflammatory parameters in ulcerative colitis: A comparison with ebselen.
Topics: Animals; Azoles; Benzene Derivatives; Catalase; Colitis; Colon; Disease Models, Animal; Inflammation | 2016 |
Progress does not just come in giant leaps: adapting techniques for the study of inflammation to novel applications.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Arthritis, Experimental; Awards and Prizes | 2017 |
Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
Topics: Azoles; Cell Movement; DNA Repair; Gene Expression Regulation; Glioblastoma; Humans; Inflammation; I | 2009 |
Ebselen reduces inflammation and microvascular perfusion failure after blunt skeletal muscle injury of the rat.
Topics: Analysis of Variance; Animals; Antioxidants; Azoles; Dimethyl Sulfoxide; Hindlimb; In Situ Nick-End | 2010 |
Protective effects of ebselen (Ebs) and para-aminosalicylic acid (PAS) against manganese (Mn)-induced neurotoxicity.
Topics: Aminosalicylic Acid; Animals; Azoles; Behavior, Animal; Biomarkers; Brain; Disease Models, Animal; I | 2012 |
The effect of ebselen on polymorphonuclear leukocyte migration to joints in rats with adjuvant arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Experimental; Azoles; Cel | 1993 |
Effect of ebselen on IL-1-induced alterations in cartilage metabolism.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis; Azoles; Cartilage; Cattle | 1998 |
Glutathione peroxidase mimics prevent TNFalpha- and neutrophil-induced endothelial alterations.
Topics: Antioxidants; Azoles; Cells, Cultured; E-Selectin; Endothelium, Vascular; Glutathione Peroxidase; Hu | 1998 |
Ebselen prevents early alcohol-induced liver injury in rats.
Topics: Alanine Transaminase; Aldehydes; Animals; Antioxidants; Azoles; Body Weight; Enteral Nutrition; Etha | 2001 |
Ebselen, a glutathione peroxidase mimetic seleno-organic compound, as a multifunctional antioxidant. Implication for inflammation-associated carcinogenesis.
Topics: Animals; Antioxidants; Azoles; Blotting, Western; Carcinogens; Cell Line; Cells, Cultured; Cyclooxyg | 2002 |
Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation.
Topics: Aerosols; Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Bronchi; Bronchoalveolar Lavage | 2002 |
The selective protection afforded by ebselen against lipid peroxidation in an ROS-dependent model of inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoles; Free Radical Scavengers; Galactose; Glucos | 1992 |
Ebselen: a new approach to the inhibition of peroxide-dependent inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Azoles; Edema; Female; Indomethacin; Inflammation; | 1987 |